The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
Stanford researchers designed an experimental molecule called TCIP3 to redirect BCL6, a protein that helps some lymphoma cells survive, toward activating genes associated with cell death. In Stanford’s August 19, 2026 report, TCIP3 eliminated tumors in mice carrying implanted human lymphoma cells—but this is preclinical research, not a treatment shown to work in people.
How does TCIP3 turn BCL6 against lymphoma cells?
BCL6 normally helps regulate gene activity. In certain B-cell lymphomas, it can silence genes that would otherwise help trigger cell death, supporting cancer-cell survival. TCIP3 is designed to change what BCL6 does rather than simply leave that silencing activity in place.
TCIP3 works through chemically induced proximity: it binds BCL6 and either P300 or CBP, bringing the proteins together. P300 and CBP add acetyl marks to BCL6 and nearby histones. According to Stanford Medicine’s 2026 account, those marks can interfere with BCL6’s gene-repressing role and support access to nearby genes associated with cell death.
Quick wins for a faster PC:
Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Clear out junk files and repair common Windows errorsFree Scan →Scan for outdated or missing drivers - takes under a minuteDriver Scan →The idea is to do two things at once: relieve BCL6’s repression and actively drive cell-death gene expression. Stanford describes the molecule as a kind of “molecular glue.” The team used structural studies and biophysical measurements to investigate how TCIP3 stabilizes the protein pairing. Stanford also reports that TCIP3 killed lab-grown lymphoma cells at very low concentrations; the report does not provide a concentration figure in its account.
What happened in the mouse experiment?
Researchers treated mice carrying implanted human lymphoma cells with TCIP3 twice daily. Stanford reports that the tumors in treated mice were gone by day 11, while tumors in control animals remained. This result is from an animal experiment; it does not show that TCIP3 works against lymphoma in people.
The same account reports no obvious signs of toxicity and no spike in inflammatory signals in the treated mice. It also notes that treatment eliminated germinal centers, structures involved in immune responses. That observation points to a possible biological trade-off, not proof that the molecule is safe for people.
Rank #2
How is this different from blocking BCL6?
Some strategies aim to block or degrade a cancer-associated protein. TCIP3 instead seeks to redirect BCL6 by recruiting P300 or CBP, so that cell-death genes are not merely released from repression but actively driven toward expression. This is a proposed mechanistic distinction, not evidence that TCIP3 is more effective than other approaches in clinical care.
Free tools Windows power users keep installed
One-click scans. No signup required.
It is also distinct from a molecule described in Stanford’s October 2024 report. That earlier strategy tethered BCL6 to CDK9, an enzyme involved in gene activation, to switch on apoptosis genes. The 2024 work and TCIP3 use different recruited partners and should not be treated as the same molecule or study.
Rank #3
What still needs to be established?
Stanford says TCIP3 needs further chemical refinement and testing in additional animal species before human trials can be considered. The reported tumor disappearance in mice is therefore not evidence of a human benefit, and the mouse observations do not establish safety in people.
Stanford mentions rheumatoid arthritis and myasthenia gravis as possible future areas to investigate because germinal-center cells are involved in some autoimmune diseases. These are research possibilities, not established uses for TCIP3.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Who is developing TCIP3?
Stanford Medicine reports that the TCIP technology is licensed to Shenandoah Therapeutics. The report also discloses company roles for senior study authors Gerald Crabtree and Nathanael Gray. These relationships are relevant context for the molecule’s path toward possible development; they do not change the current evidence stage, which remains preclinical.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Quick Recap
Best Value
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
